Canarb, 120 mg 30 pcs.

Fimasartan is a non-peptide angiotensin II receptor antagonist (type AT1) for oral administration.

Angiotensin II is a key effector compound of the RAAS, which plays an important role in BP regulation and pathogenesis of arterial hypertension. Angiotensin II increases BP due to a significant vasoconstrictor effect and increase of ROS, activation of epinephrine production, release of aldosterone, influence on sodium reabsorption in distal renal tubules and increase of the blood pressure. Its action is mediated through specific angiotensin receptors, while the main physiological effects, including adverse ones, are mediated by AT1-receptors.

The action of fimasartan is due to selective binding to AT1-receptors of angiotensin II: fimasartan has no partial agonist effect on angiotensin II receptors, which is typical for peptide blockers of angiotensin II receptors (such as saralazine). In a study of various animal models, fimasartan effectively and dose-dependently reduced BP after single or repeated oral and IV administration.

Indications

Active ingredient

Composition

Excipients:

– Lactose monohydrate – 87.98 mg;

– Microcrystalline cellulose – 23.5 mg;

– Croscarmellose sodium – 45 mg;

– Hydroxypropyl cellulose – 7 mg;

– Magnesium stearate – 4.5 mg.

Shell contents:

– Opadray 03B63253 orange – 7.5 mg (hypromellose (E464) 62.5%, titanium dioxide (E171) 25.23%, macrogol (E1521) 6.25%,

Sunset Yellow dye (E110) 6%, iron oxide black dye (E172) 0.01%, iron oxide yellow dye (E172) 0.01%);

– carnauba wax (E903) – 0.5 mg.

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Safety of fimasartan in a Korean population was studied in 406 patients out of 852 patients with essential hypertension who received fimasartan in doses ranging from 60 to 120 mg for 4 to 12 weeks and who were included in clinical trials and selected for safety analysis (ie, whose information formed the safety database). 85 patients received fimasartan for 6 months or longer. Most of the reported adverse events were mild to moderate in severity and transient, and the frequency of occurrence was independent of the drug dose. The most frequent adverse events were headache and dizziness.

Table 1 lists the adverse events (ie, adverse events considered to be definitely related, probably related, or possibly related to fimasartan) according to the WHO frequency classification of adverse reactions reported in clinical trials with fimasartan in Korea.

Table 1. Adverse reactions due to the use of fimasartan1

Overdose